|
|
Volumn 4, Issue 8, 2008, Pages 387-
|
|
Fast forward for systemic lupus erythematosus clinical trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
B CELL ACTIVATING FACTOR;
BIOLOGICAL PRODUCT;
CD28 ANTIGEN;
CD40 LIGAND;
CD40 LIGAND MONOCLONAL ANTIBODY;
ETANERCEPT;
INTERLEUKIN 6;
MONOCLONAL ANTIBODY CD28;
ANTIGEN EXPRESSION;
B LYMPHOCYTE;
CLINICAL RESEARCH;
CLINICAL TRIAL;
CYTOKINE PRODUCTION;
DOSE RESPONSE;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG SCREENING;
DRUG TARGETING;
EDITORIAL;
GENETIC VARIABILITY;
HUMAN;
IMMUNOMODULATION;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SYSTEMIC LUPUS ERYTHEMATOSUS;
T LYMPHOCYTE;
TREATMENT RESPONSE;
CLINICAL TRIALS AS TOPIC;
HUMANS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
|
|
EID: 48749098633
PISSN: 17458382
EISSN: 17458390
Source Type: Journal
DOI: 10.1038/ncprheum0866 Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|
